FDA approves Imbruvica (ibrutinib) for mantle cell lymphoma (MCL)
Second drug with breakthrough therapy designation to receive FDA approval. Washington, DC (US) – November 13, 2013 — The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.